By Abujah Racheal
In an interview with the Nigeria News Agency (NAN) on Monday in Abuja, Shuaib said there were several COVID-19 vaccine candidates.
He said while some had been approved for emergency use by the World Health Organization (WHO), others were still in different stages of clinical trials for possible approval.
According to him, the COVID-19 vaccine candidates are of various categories according to their mechanism of action such as inactivated or weakened virus vaccines.
He explained that in the formulation of the COVID-19 vaccine, an inactivated or weakened virus is used so that it does not cause disease, but generates an immune response.
He also said that there are protein-based vaccines, which use harmless fragments of proteins or protein shells that mimic the COVID-19 virus to safely generate an immune response.
He added that the viral vector vaccines used a virus that had been genetically engineered so as not to cause disease but would produce coronavirus proteins to safely generate an immune response.
He added that the ribonucleic acid (RNA) and deoxyribonucleic acid (DNA) vaccines used a cutting edge approach that used genetically engineered RNA or DNA to generate a protein that safely caused an immune response.
NAN reports that 1.09 million Nigerians received the first dose of the Astrazeneca vaccine.
Short Link: https://wp.me/pcj2iU-3yYc
- JUSUN urges FG to deduct Judiciary funds from May FAAC
- Eid-el-Fitr: APC urges Nigerians to pray for country’s leaders, peace, unity
- WHO panel urges bold overhaul of pandemic prevention measures
- $540bn remittance flow reaches low-and-middle-income countries in 2020- WB
- Arsenal dent Chelsea’s Champions League push
- Kalu salutes Ekweremadu at 59
- NECO: 115 inmates credit English, Maths in Enugu
- Infinix Releases Award Winning NOTE 10 Pro Series Powerful Performance. Iconic design
- Eid-el-fitr: Yahaya Bello calls for national integration